Monitoring occupational exposure to cancer chemotherapy drugs

American Journal of Health-System Pharmacy

Volumn 53, Issue 22, 1996, Pages 2713-2723

  Baker, Ellen S ^a   Connor, Thomas H ^b  

^a NASA HEADQUARTERS   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Antineo plastic agents; Compliance; Guidelines; Health professions; Metabolism; Methodology; Safety; Tests, laboratory; Toxicity, environmental; Urine levels

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; DNA; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; SACCHARIC ACID; SULFIDE;

ANALYTIC METHOD; BIOLOGICAL MONITORING; CANCER CHEMOTHERAPY; CHROMOSOME ABERRATION; HUMAN; MICRONUCLEUS TEST; MUTAGENICITY; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; REVIEW; SISTER CHROMATID EXCHANGE; URINALYSIS;

EID: 0029987302     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/53.22.2713     Document Type: Review

References (146)

1. Cancer facts & figures - 1996. Atlanta: American Cancer Society; 1996.
2. Ng LM. Possible hazards of handling antineoplastic drugs. Pediatrics. 1970; 46:648.
3. Donner AL. Possible risk of working with antineoplastic drugs in horizontal laminar flow hoods. Am J Hosp Pharm. 1978; 35:900. Letter.
4. Falck K, Gröhn P, Sorsa M et al. Mutagenicity in urine of nurses handling cytostatic drugs. Lancet. 1979; 1:1250-1.
5. Kleinberg ML, Quinn MJ. Airborne drug levels in a laminar-flow hood. Am J Hosp Pharm. 1981; 38:1301-3.
6. DeWerk Neal A, Wadden RA, Chiou WL. Exposure of hospital workers to airborne antineoplastic agents. Am J Hosp Pharm. 1983; 40:597-601.
7. Sorsa M, Pyy L, Salomaa S et al. Biological and environmental monitoring of occupational exposure to cyclophosphamide in industry and hospitals. Mutat Res. 1988; 204:465-79.
8. McDevitt JJ, Lees PSJ, McDiarmid MA. Exposure of hospital pharmacists and nurses to antineoplastic agents. J Occup Med. 1993; 35:57-60.
9. Sessink PJM, Anzion RB, Van den Broek PHH et al. Detection of contamination with antineoplastic agents in a hospital pharmacy department. Pharm Weekbl Sci. 1992; 14:16-22.
10. Sessink PJM, Boer KA, Scheefhals APH et al. Occupational exposure to antineoplastic agents at several departments in a hospital: environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int Arch Occup Environ Health. 1992; 64:105-12.
11. Sessink PJM, Timmersmans JL, Anzion RB et al. Assessment of occupational exposure of pharmaceutical plant workers to 5-fluorouracil. J Occup Med. 1994; 36:79-83.
12. Sessink PJM, Friemèl NSS, Anzion RBM et al. Biological and environmental monitoring of occupational exposure of pharmaceutical plant workers to methotrexate. Int Arch Occup Environ Health. 1994; 65:401-3.
13. Sessink PJM, Van de Kerkhof MCA, Anzion RB et al. Environmental contamination and assessment of exposure to antineoplastic agents by determination of cyclophosphamide in urine of exposed pharmacy technicians: is skin absorption an important exposure route? Arch Environ Health. 1994; 49:165-9.
14. Office of Occupational Medicine, Occupational Safety and Health Administration. Guidelines for cytotoxic (antineoplastic) drugs. Washington, DC: U.S. Department of Labor; 1986 Jan. (Instructional publication 8-1.1).
15. Instruction TED 1.15. Directorate of technical support, Occupational Safety and Health Administration. Controlling occupational exposure to hazardous drugs. Washington, DC: U.S. Department of Labor; 1995 Sep. (Instruction TED 1.15, Section V, Ch.3).
16. American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic drugs in hospitals. Am J Hosp Pharm. 1985; 42:131-7.
17. American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm. 1990; 47:1033-49.
18. American Medical Association Council on Scientific Affairs. Guidelines for handling parenteral antineoplastics. JAMA. 1985; 253:1590-2.
19. Recommendations for handling cytotoxic agents. Providence, RI: National Study Commission on Cytotoxic Exposure; 1987 Sep.
20. Oncology Nursing Society. Cancer chemotherapy guidelines: modules I-V, Pittsburgh: Oncology Nursing Society; 1988.
21. Gullo SM. Safe handling of antineoplastic drugs: translating the recommendations into practice. Oncol Nurs Forum. 1988; 15:595-601.
22. Jones RB, Frank R, Mass T. Safe handling of chemotherapeutic agents: a report from the Mount Sinai Medical Center. CA Cancer J Clin. 1983; 33:257-63.
23. LeRoy ML, Roberts MJ, Theisen JA. Procedures for handling antineoplastic injections in comprehensive cancer centers. Am J Hosp Pharm. 1983; 40:601-3.
24. Stellman JM, Aufiero BM, Taub RN. Assessment of potential exposure to antineoplastic agents in the health care setting. Prev Med. 1984; 13:245-55.
25. Barry LK, Booher RB. Promoting the responsible handling of antineoplastic agents in the community. Oncol Nurs Forum. 1985; 12:41-6.
26. Stajich GV, Barnett CW, Turner SV et al. Protective measures used by oncologic office nurses handling parenteral antineoplastic agents. Oncol Nurs Forum. 1986; 13:47-9.
27. Cohen IA, Newland SJ, Kirking DM. Injectable-antineoplastic-drug practices in Michigan hospitals. Am J Hosp Pharm. 1987; 44:1096-105.
28. Gregoire RE, Segal R, Hale KM. Handling antineoplastic-drug admixtures at cancer centers: practices and pharmacist attitudes. Am J Hosp Pharm. 1987; 44:1090-5.
29. Valanis B, Shortridge L. Self protective practices of nurses handling antineoplastic drugs. Oncol Nurs Forum. 1987; 14:23-7.
30. Valanis B, McNeil V, Driscoll K. Staff members' compliance with their facility's antineoplastic drug handling policy. Oncol Nurs Forum. 1991; 18:571-6.
31. Mayer DK. Hazards of chemotherapy: implementing safe handling practices. Cancer. 1992; 70 (suppl):988-92.
32. Valants B, Vollmer WM, Labuhn K et al. Antineoplastic drug handling protection after OSHA guidelines: comparison by profession, handling activity and work site. J Occup Med. 1992; 34:149-55.
33. Mahon SM, Casperson DS, Yackzan S et al. Safe handling practices of cytotoxic drugs: the results of a chapter survey. Oncol Nurs Forum. 1994; 21:1157-65.
34. Nieweg RMB, de Boer M, Dubbleman RC et al. Safe handling of antineoplastic drugs. Cancer Nurs. 1994; 17:501-11.
35. Sorsa M, Hemminki K, Vainio H. Occupational exposure to anticancer drugs - potential and real hazards. Mutat Res. 1985; 154:135-49.
36. Stellman JM, Zoloth SR. Cancer chemotherapeutic agents as occupational hazards: a literature review. Cancer Invest. 1986; 4:127-35.
37. Rogers B. Investigations of work-related exposures to antineoplastic agents: an overview of the literature. Semin Occup Med. 1987; 2:83-9.
38. Valanis BG, Vollmer WM, Labuhn KT et al. Association of antineoplastic drug handling with acute adverse effects in pharmacy personnel. Am J Hosp Pharm. 1993; 50:455-62.
39. Niklasson B, Bjorkner B, Hansen L. Occupational contact dermatitis from antitumor agent intermediates. Contact Dermatitis. 1990; 22:233-5.
40. Reynolds RD, Ignoffo R, Lawrence J et al. Adverse reactions to AMSA in medical personnel. Cancer Treat Rep. 1982; 66:1885. Letter.
41. McDiarmid M, Egan T. Acute occupational exposure to antineoplastic agents. J Occup Med. 1988; 30:984-7.
42. Ladik CF, Stoehr GP, Maurer MA. Precautionary measures in the preparation of antineoplastics. Am J Hosp Pharm. 1980; 37:1184,1186. Letter.
43. Lassila O, Toivanen A, Nordman E. Immune function in nurses handling cytostatic drugs. Lancet. 1980; 2:482. Letter.
44. Jochimsen PR, Corder MP, Anthony P et al. Preparation and administration of chemotherapy: haematological consequences for hospital-based nurses. Med Toxicol. 1988; 3:59-63.
45. Sotaniemi EA, Sutinen S, Arranto AJ et al. Liver damage in nurses handling cytostatic agents. Acta Med Scand. 1983; 214:181-9.
46. Levin LI, Holly EA, Seward JP. Bladder cancer in a 39-year-old female pharmacist. J Natl Cancer Inst. 1993; 85:1089-90.
47. Gabriele P, Airoldi M, Succo G et al. Undifferentiated nasopharyngeal-type carcinoma in a nurse handling cytostatic agents. Eur J Cancer B Oral Oncol. 1993; 29:153. Letter.
48. Slimowitz R, Mitrik LJ. Studies on long-term, not short-term, effects of antineoplastic drug handling are needed. Am J Hosp Pharm. 1993; 50:1862-3. Letter.
49. Shortbridge LA, Lemasters GK, Valanis B et al. Menstrual cycles in nurses handling antineoplastic drugs. Cancer Nurs. 1995; 18:439-44.
50. Selevan SG, Lindbohm M-L, Hornung RW et al. A study of occupational exposure to antineoplastic drugs and fetal loss in nurses. N Engl J Med. 1985; 313:1173-8.
51. Stucker I, Caillard J-F, Collin R et al. Risk of spontaneous abortion among nurses handling antineoplastic drugs. Scand J Work Environ Health. 1990; 16:102-7.
52. Saurel-Cubizolles MJ, Job-Spira N, Estryn-Behar M. Ectopic pregnancy and occupational exposure to antineoplastic drugs. Lancet. 1993; 341:1169-71.
53. Hemminki K, Kyyrönen P, Lindbohm ML. Spontaneous abortions and malformations in the offspring of nurses exposed to anaesthetic gases, cytostatic drugs, and other potential hazards in hospitals, based on registered information of outcome. J Epidemiol Community Health. 1985; 39:141-7.
54. McDonald AD, McDonald JC, Armstrong B et al. Congenital defects and work in pregnancy. Br J Ind Med. 1988; 45:581-8.
55. Skov T, Maarup B, Olsen J et al. Leukaemia and reproductive outcome among nurses handling antineoplastic drugs. Br J Ind Med. 1992; 49:855-61.
56. Murphy CP, Goldspiel BR, Koeller J. Cost of implementing Veterans Administration directives for handling antineoplastic agents. Am J Hosp Pharm. 1987; 44:788-91.
57. Sessink PJM, Cerná M, Rössner P et al. Urinary cyclophosphamide excretion and chromosomal aberrations in peripheral blood lymphocytes after occupational exposure to antineoplastic agents. Mutat Res. 1994; 309:193-9.
58. Hirst M, Tse S, Mills DG et al. Caution on handling antineoplastic drugs. N Engl J Med. 1983; 309:188-9.
59. Hirst M, Tse S, Mills DG et al. Occupational exposure to cyclophosphamide. Lancet. 1984; 1:186-8.
60. Evelo CTA, Bos RP, Peters JGP et al. Urinary cyclophosphamide assay as a method for biological monitoring of occupational exposure to cyclophosphamide. Int Arch Occup Environ Health. 1986; 58:151-5.
61. Ensslin AS, Pethran A, Schierl R et al. Urinary platinum in hospital personnel occupationally exposed to platinum-containing antineoplastic drugs. Int Arch Occup Environ Health. 1994; 65:339-42.
62. Ensslin AS, Stoll Y, Pethran A et al. Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs. Occup Environ Med. 1994; 51:229-33.
63. Venitt S, Crofton-Sleigh C, Hunt J et al. Monitoring exposure of nursing and pharmacy personnel to cytotoxic drugs: urinary mutation assays and urinary platinum as markers of absorption. Lancet. 1984; 1:74-7.
64. Connor TH. An evaluation of the permeability of disposable polypropylene-based protective gowns to a battery of cancer chemotherapy drugs. Appl Occup Environ Hyg. 1993; 8:785-9.
65. Connor TH. Permeability testing of glove materials for use with cancer chemotherapy drugs. Oncology. 1995; 52:256-9.
66. Norppa H, Sorsa M, Vainio H et al. Increased sister chromatid exchange frequencies in lymphocytes of nurses handling cytostatic drugs. Scand J Work Environ Health. 1980; 6:299-301.
67. Waksvik H, Klepp O, Brogger A. Chromosome analyses of nurses handling cytostatic agents. Cancer Treat Rep. 1981; 65:607-10.
68. Anderson RW, Puckett WH, Dana WJ et al. Risk of handling injectable antineoplastic agents. Am J Hosp Pharm. 1982; 39:1881-7.
69. Bos RP, Leenaars AO, Theuws JLG et al. Mutagenicity of urine from nurses handling cytostatic drugs, influence of smoking. Int Arch Occup Environ Health. 1982; 50:359-69.
70. Jagun O, Ryan M, Waldron HA. Urinary thioether excretion in nurses handling cytotoxic drugs. Lancet. 1982; 2:443-4.
71. Nguyen TV, Theiss JC, Matney TS. Exposure of pharmacy personnel to mutagenic antineoplastic drugs. Cancer Res. 1982; 42:4792-6.
72. Hoffman DM. Lack of urine mutagenicity of nurses administering pharmacy prepared doses of antineoplastic agents. Am J Intravenous Ther Clin Nutr. 1983; 10:28-31.
73. Kolmodin-Hedman B, Hartvig P, Sorsa M et al. Occupational handling of cytostatic drugs. Arch Toxicol. 1983; 54:25-33.
74. Ratcliffe JM. Occupational exposure to cancer chemotherapeutic agents in pharmacists and nurses. Washington, DC: U.S. Government Printing Office; 1983. (National Institute for Occupational Safety and Health industry-wide study E:-80-41.)
75. Stiller A, Obe G, Boll I et al. No elevation of the frequencies of chromosomal alterations as a consequence of handling cytostatic drugs: analyses with peripheral blood and urine of hospital personnel. Mutat Res. 1983; 121:253-9.
76. Chrysostomou A, Seshadri R, Morley AA. Mutation frequency in nurses and pharmacists working with cytotoxic drugs. Aust N Z J Med. 1984; 14:831-4.
77. Gibson JF, Gompertz D, Hedworth-Whitty SB. Mutagenicity of urine from nurses handling cytotoxic drugs. Lancet. 1984; 1:100-1.
78. Nikula E, Kiviniitty K, Leisti J et al. Chromosome aberrations in lymphocytes of nurses handling cytostatic agents. Scand J Work Environ Health. 1984; 10:71-4.
79. Barale R, Sozzi G, Toniolo P et al. Sister-chromatid exchanges in lymphocytes and mutagenicity in urine of nurses handling cytostatic drugs. Mutat Res. 1985; 157:235-40.
80. Cloak MM, Connor TH, Stevens KR et al. Occupational exposure of nursing personnel to antineoplastic agents. Oncol Nurs Forum. 1985; 12:33-9.
81. Everson RB, Ratcliffe JM, Flack PM et al. Detection of low levels of urinary mutagen excretion by chemotherapy workers which was not related to occupational drug exposures. Cancer Res. 1985; 45:6487-97.
82. Lovejoy N, Powers L, Flessel P et al. Mutagenicity in urine of hospital workers who prepare and administer chemotherapy agents. Environ Mutagen. 1985; 7(suppl 3):5. Abstract.
83. Benhamou S, Callais F, Sancho-Garnier H et al. Mutagenicity in urine from nurses handling cytostatic agents. Eur J Cancer Clin Oncol. 1986; 22:1489-93.
84. Connor TH, Theiss JC, Anderson RW et al. Re-evaluation of urine mutagenicity of pharmacy personnel exposed to antineoplastic agents. Am J Hosp Pharm. 1986; 43:1236-9.
85. Friederich U, Molko F, Hofmann V et al. Limitations of the salmonella/mammalian microsome assay (Ames test) to determine occupational exposure to cytostatic drugs. Eur J Cancer Clin Oncol. 1986; 22:567-75.
86. Jordan DK, Patil SR, Jochimsen PR et al. Sister chromatid exchange analysis in nurses handling antineoplastic drugs. Cancer Invest. 1986; 4:101-7.
87. Pohlová H, Cerná M, Rössner P. Chromosomal aberrations, SCE and urine mutagenicity in workers occupationally exposed to cytostatic drugs. Mutat Res. 1986; 174:213-7.
88. Stucker I, Hirsch A, Doloy T et al. Urine mutagenicity, chromosomal abnormalities and sister chromatid exchanges in lymphocytes of nurses handling cytostatic drugs. Int Arch Occup Environ Health. 1986; 57:195-205.
89. Bayhan A, Burgaz S, Karakaya AE. Urinary thioether excretion in nurses at an oncologic department. J Clin Pharm Ther. 1987; 12:303-6.
90. Courtois YA, Beaubestre C, Benhamou S et al. Determination de la génotoxicité urinaire: application au dépistage de l'exposition tabagique et/ou professionnelle. Ann Pharmaceutiques Francaises. 1987; 45:289-300.
91. Rogers B, Emmett EA. Handling antineoplastic agents: urine mutagenicity in nurses. Image J Nurs Sch. 1987; 19:108-13.
92. Burgaz S, Özdamar YN, Karakaya AE. A signal assay for the detection of genotoxic compounds: applications on the urines of cancer patients on chemotherapy and of nurses handling cytotoxic drugs. Hum Toxicol. 1988; 7:557-60.
93. Caudell KA, Vredevoe DL, Dietrich MF et al. Quantification of urinary mutagens in nurses during potential antineoplastic agent exposure: a pilot study with concurrent environmental and dietary control. Cancer Nurs. 1988; 11:41-50.
94. Poyen D, DeMeó MP, Botta A et al. Handling of cytostatic drugs and urine mutagenesis. Int Arch Occup Environ Health. 1988; 61:183-8.
95. Rössner P, Cerná M, Pokorána D et al. Effect of ascorbic acid prophylaxis on the frequency of chromosome aberrations, urine mutagenicity and nucleolus test in workers occupationally exposed to cytostatic drugs. Mutat Res. 1988; 208:149-53.
96. Krepinsky A, Bryant DW, Davison L et al. Comparison of three assays for genetic effects of antineoplastic drugs on cancer patients and their nurses. Environ Mol Mutagen. 1990; 15:83-92.
97. Oestreicher U, Stephan G, Glatzel M. Chromosome and SCE analysis in peripheral lymphocytes of persons occupationally exposed to cytostatic drugs handled with and without use of safety covers. Mutat Res. 1990; 242:271-7.
98. Sarto F, Trevisan A, Tomanin R et al. Chromosomal aberrations, sister chromatid exchanges, and urinary thioethers in nurses handling antineoplastic drugs. Am J Ind Med. 1990; 18:689-95.
99. Cooke J, Williams J, Morgan RJ et al. Use of cytogenetic methods to determine mutagenic changes in the blood of pharmacy personnel and nurses who handle cytotoxic agents. Am J Hosp Pharm. 1991; 48:1199-205.
100. Milkovic-Kraus S, Horvat D. Chromosomal abnormalities among nuises occupationally exposed to antineoplastic drugs. Am J Ind Med. 1991; 19:771-4.
101. Sardas S, Gök S, Karakaya AE. Sister chromatid exchanges in lymphocytes of nurses handling antineoplastic drugs. Toxicol Lett. 1991; 55:311-5.
102. Thiringer G, Granung G, Holmén A et al. Comparison of methods for the biomonitoring of nurses handling antitumor drugs. Scand J Work Environ Health. 1991; 17:133-8.
103. Goloni-Bertollo EM, Tajara EH, Manzato AJ et al. Sister chromatid exchanges and chromosome aberrations in lymphocytes of nurses handling antineoplastic drugs. Int J Cancer. 1992; 50:341-4.
104. Harris PE, Connor TH, Stevens KR et al. Cytogenetic assessment of occupational exposure of nurses to antineoplastic agents. J Occup Med Toxicol. 1992; 1:243-54.
105. McDiarmid MA, Kolodner K, Humphrey F et al. Baseline and phosphoramide mustard-induced sister-chromatid exchanges in pharmacists handling anti-cancer drugs. Mutat Res. 1992; 279:199-204.
106. Milkovic-Kraus S, Kraus O, Kršnjavi H et al. Environmental effects on chromosomes in oncology and radiology department personnel. Prev Med. 1992; 21:498-502.
107. Anwar WA, Salama SI, Serafy MM et al. Chromosomal aberrations and micronucleus frequency in nurses occupationally exposed to cytotoxic drugs. Mutagenesis. 1994; 9:315-7.
108. Dubeau H, Zazi W, Baron C et al. Effects of lymphocyte subpopulations on the clonal assay of HPRT mutants: occupational exposure to cytostatic drugs. Mutat Res. 1994; 321:147-57.
109. Machado-Santelli GM, Cerqueira EM, Oliveira CT et al. Biomonitoring of nurses handling antineoplastic drugs. Mutat Res. 1994; 332:203-8.
110. Newman MA, Valanis BG, Schoeny RS et al. Urinary biological monitoring markers of anticancer drug exposure in oncology nurses. Am J Public Health. 1994; 84:852-5.
111. Roth S, Norppa H, Järventaus H et al. Analysis of chromosomal aberrations, sister chromatid exchanges and micronuclei in peripheral lymphocytes of pharmacists before and after working with cytostatic drugs. Mutat Res. 1994; 325:157-62.
112. Brumen V, Horvat D, Trošic I. Potential genotoxic risk related to simultaneous exposure to radionuclides and cytostatics. Am J Ind Med. 1995; 27:871-6.
113. DeMeó MP, Mérono S, DeBaille AD et al. Monitoring exposure of hospital personnel handling cytostatic drugs and contaminated materials. Int Arch Occup Environ Health. 1995; 66:363-8.
114. Fuchs J, Hengstler JG, Jung D et al. DNA damage in nurses handling antineoplastic agents. Mutat Res. 1995; 342:17-23.
115. Thulin H, Sundberg E, Hansson K et al. Occupational exposure to nor-nitrogen mustard: chemical and biological monitoring. Toxicol Ind Health. 1995; 11:89-97.
116. Hubbard SA, Green MHL, Gatehouse D. The fluctuation test in bacteria. In: Kilbey BJ, Legator M, Nichols W et al., eds. Handbook of mutagenicity procedures. Amsterdam: Elsevier; 1984:141-59.
117. Green MHL. Mutagen testing using Trp + reversion in Escher- ichia coli. In: Kibley BJ, Legator M, Nichols W et al., eds. Handbook of mutagenicity procedures. Amsterdam: Elsevier; 1984:161-87.
118. Ames BN, McCann J, Yamasaki E. Methods for detecting carcinogens and mutagens with the salmonella/mammalian-microsome mutagenicity test. Mutat Res. 1975; 31:347-64.
119. McCann J, Choi E, Yamasaki E et al. Detection of carcinogens as mutagens in the salmonella/microsome test: assay of 300 chemicals. Proc Natl Acad Sci USA. 1975; 72:5135-9.
120. Benedict WF, Baker MS, Haroun L et al. Mutagenicity of cancer chemotherapeutic agents in the salmonella/microsome test. Cancer Res. 1977; 37:2209-13.
121. Matney T, Nguyen T, Connor T. Genotoxic classification of anticancer drugs. Teratogenesis Carcinog Mutagen. 1985; 5:319-28.
122. Tuffnell PG, Gannon MT, Dong A et al. Limitations of urinary mutagen assays for monitoring occupational exposure to antineoplastic drugs. Am J Hosp Pharm. 1986; 43:344-8.
123. Vainio H, Sorsa M, Rantanen J et al. Biological monitoring in the identification of the cancer risk of individuals exposed to chemical carcinogens. Scand J Work Environ Health. 1981; 7:241-51.
124. Gibson JF, Baxter PJ, Hedworth-Whitty RB et al. Urinary mutagenicity assays: a problem arising from the presence of histidine associated growth factors in XAD-2 prepared urine concentrates, with particular relevance to assays carried out using the bacterial fluctuation test. Carcinogenesis. 1983; 4:1471-6.
125. Sasson IM, Coleman DT, LaVoie EJ et al. Mutagens in human urine: effects of cigarette smoking and diet. Mutat Res. 1985; 158:149-57.
126. Griesemer RA, Venitt S. Long-term and short-term assays for carcinogens: a critical appraisal. IARC Sci Publ; 1985; 83:409-38.
127. Rynard S. Urine mutagenicity assays. In: Hulka BS, Wilcosky TC, Griffith JD, eds. Biological markers in epidemiology. New York: Oxford Univ. Press; 1990:56-77.
128. Wolff S. Difficulties in assessing the human health effects of mutagenic carcinogens by cytogenetic analyses. Cytogenet Cell Genet. 1982; 33:7-13.
129. Sorsa M, Hemminki K, Vainio H. Biologic monitoring of exposure to chemical mutagens in the occupational environment. Teratogenesis Carcinog Mutagen. 1982; 2:137-50.
130. Forni A. Chromosomal aberrations in monitoring exposure to mutagens-carcinogens. In: Monitoring human exposure to carcinogenic and mutagenic agents. IARC Sci Publ. 1984; 59:325-37.
131. Sorsa M. Monitoring of sister chromatid exchange and mi-cronuclei as biological endpoints. In: Monitoring human exposure to carcinogenic and mutagenic agents. IARC Sci Publ. 1984; 59:339-49.
132. Tucker JD, Ashworth LK, Johnston GR et al. Variation in the human lymphocyte sister-chromatid exchange frequency: results of a long-term study. Mutat Res. 1988; 204:435-44.
133. Carrano AV, Natarajan AT. Considerations for population monitoring using cytogenetic techniques. Mutat Res. 1988; 204:379-406.
134. Lambert B, Bredberg A, McKenzie W et al. Sister chromatid exchange in human populations: the effect of smoking, drug treatment and occupational exposure. Cytogenet Cell Genet. 1982; 33:62-7.
135. Mäki-Paakkanen J, Walles S, Osterman-Golkar S et al. Single-strand breaks, chromosome aberrations, sister-chromatid exchanges and micronuclei in blood lymphocytes of workers exposed to styrene during the production of reinforced plastics. Environ Mol Mutagen. 1991; 17:27-31.
136. Karelová J, Jablonická A, Gavora J et al. Chromosome and sister-chromatid exchange analysis in peripheral lymphocytes, and mutagenicity of urine in anesthesiology personnel. Int Arch Occup Environ Health. 1992; 64:303-6.
137. De Jong G, van Sittert NJ, Natarajan AT. Cytogenetic monitoring of industrial populations potentially exposed to genotoxic chemicals and of control populations. Mutat Res. 1988; 204:451-64.
138. Hogstedt B. Micronuclei in lymphocytes with preserved cytoplasm: a method for assessment of cytogenetic damage in man. Mutat Res. 1984; 130:63-72.
139. Albertini RJ, Sylwester DL. 6-Thioguanine-resistant lymphocytes in human blood. In: Kibley BJ, Legator M, Nichols W et al., eds. Handbook of mutagenicity test procedures. Amsterdam: Elsevier; 1984:357-72.
140. U.S. Nuclear Regulatory Commission. Operating philosophy for maintaining occupational radiation exposures as low as is reasonably achievable. Washington,DC: U.S. Government Printing Office; 1975 Sep. (Regulatory guide 8.10).
141. U.S. Nuclear Regulatory Commission. Information relevant to ensuring that occupational radiation exposures at medical institutions will be as low as reasonably achievable. Washington, DC: U.S. Government Printing Office; 1982 Oct. (Regulatory guide 8.18).
142. Parillo VL. Documentation forms for monitoring occupational surveillance of healthcare workers who handle cytotoxic drugs. Oncol Nurs Forum. 1994; 21:115-20.
143. Valanis B. Environmental and direct measures of exposure. Occup Med. 1986; 1:431-44.
144. Shulman LN. The biology of alkylating-agent cellular injury. Hematol Oncol Clin North Am. 1993; 7:325-35.
145. Fichtinger-Schepman AM, van Oosterom AT, Lohman PHM et al. cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II). Cancer Res. 1987; 47:3000-4.
146. Baan RA, Lohman PHM, Fichtinger-Schepman AMJ et al. Immunochemical approach to detection and quantitation of DNA adducts resulting from exposure to genotoxic agents. In: Sorsa M, Norppa H, eds. Monitoring of occupational genotoxicants. New York: Liss; 1986:135-46.